Metanor Resources (MEAOF) 0.0420 $MEAOF Metanor Reports

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Metanor Resources (MEAOF) 0.0420 $MEAOF

Metanor Reports Larger Intersection With 6.14 g/t Over 15 Meters at Bachelor Mine
Marketwired - Thu Apr 09, 7:55AM CDT
Metanor Resources Inc. ("Metanor" (TSX VENTURE: MTO) is pleased to report larger intersections in the holes 13-154 and 13-160 than was previously reported March 30th 2015.
MTO.VN: 0.045 (unch)

Metanor Intersects 8.64 g/T Over 5.8 Meters at Bachelor Mine
Marketwired - Mon Mar 30, 8:12AM CDT
Metanor Resources Inc. ("Metanor" (TSX VENTURE: MTO) is pleased to announce that it has intersected 8.64 g/T over 5.8 meters near the drill station on level 13 at the Bachelor Mine.
MTO.VN: 0.045 (unch)

Metanor Resources Inc.: Maturity Date of Debentures Extended 24 Months
Marketwired - Fri Mar 27, 3:55PM CDT
Metanor Resources Inc. ("Metanor" (TSX VENTURE: MTO) announces that it has repurchased $1M in principal value, from the outstanding $10M in 10% Subordinated Secured Convertible Debentures issued August 22, 2012 (the "Debentures" and that the maturity date on the remaining Debentures (in the aggregate principal amount of $9M) has been extended by 24 months to August 22, 2017.
MTO.VN: 0.045 (unch)

Metanor: Update on Private Placement
Marketwired - Fri Mar 20, 9:53AM CDT
Metanor Resources Inc. ("Metanor" (TSX VENTURE: MTO) announces that the terms of the private placement previously announced on February 23, 2015, have been amended and Metanor will be offering, through Secutor Capital Management Corp. and Marquest Capital Markets: i) a maximum 40,000,000 units priced at $0.05 each, which consist of one common share and one common share purchase warrant having an exercise price of $0.055 and a term of 36 months, for maximum proceeds of $2,000,000; and (ii) 35,000,000 flow-through units priced at $0.05 each, which consist of one flow-through common share and one half of one common share purchase warrant having an exercise price of $0.055 and a term of 36 months, for maximum proceeds of $1,750,000 and gross aggregate proceeds of $3,750,000.
MTO.VN: 0.045 (unch)

Metanor Intersects 6.1 g/T Over 6.8 Meters at Bachelor Mine
Marketwired - Tue Mar 17, 7:52AM CDT
Metanor Resources Inc. ("Metanor" (TSX VENTURE: MTO) is pleased to announce that it has intersected 6.1 g/T over 6.8 meters near the drill station on level 13 at Bachelor Mine.
MTO.VN: 0.045 (unch)

Metanor Resources Inc.: New Gold Corridor at Bachelor Mine
Marketwired - Thu Mar 12, 7:02AM CDT
Metanor Resources Inc. ("Metanor" (TSX VENTURE: MTO) is pleased to announce that it has identified a new corridor with gold grades, located 860 m south of the Bachelor Mine.
MTO.VN: 0.045 (unch)

Metanor Produces 3,425 Ounces During the Month of January
Marketwired - Fri Feb 13, 12:48PM CST
Metanor Resources Inc. ("Metanor" (TSX VENTURE: :MTO) announces that it has produced 3,425 ounces of gold during the month of January 2015.
MTO.VN: 0.045 (unch)

Metanor Produced 8,332 Ounces During the Quarter Ending December 31st 2014
Marketwired - Mon Jan 19, 8:51AM CST
Metanor Resources Inc. ("Metanor" (TSX VENTURE: MTO) announces that it has produced 8,332 ounces of gold during the quarter ending December 31st 2014.
MTO.VN: 0.045 (unch)

Metanor Resources: A High-Grade Gold Producer
David Desjardins - at Seeking Alpha - Fri Jan 02, 8:46AM CST


Metanor Reports its Financial Results for the Quarter Ended September 30th, 2014
Marketwired - Fri Nov 28, 4:46PM CST
Metanor Resources Inc. ("Metanor" (TSX VENTURE: MTO) is pleased to report on its financial results for the quarter ended September 30th 2014 (Q1). This press release should be read in conjunction with Metanor's quarterly financial statements and accompanying notes for the period ended September 30th 2014 and related Management's Discussion and Analysis (MD&A), which can be found at www.metanor.ca or on SEDAR www.sedar.com. All amounts are in Canadian dollars unless otherwise stated.
MTO.VN: 0.045 (unch)

Metanor Begins an Exploration Program Near the Old Coniagas Mine
Marketwired - Mon Nov 10, 9:03AM CST
Metanor Resources Inc. ("Metanor" (TSX VENTURE: MTO) is pleased to announce the beginning of an exploration campaign on surface near its Coniagas property, located 250 km North-East of Val d'Or in Abitibi, and 1.6 km from the Bachelor Mine operated by Metanor. The Coniagas Mine, a past producing mine , extracted 718,500 T at 10.8% Zn, 1% Pb, and 183 g/T Ag (Carrier & Davy, 2005) during the 60's.
MTO.VN: 0.045 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 9

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 26

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading

Top 5 Most Recently Viewed Articles

BioSyent Inc. to Announce Q3 Financial Results This Month

Updated Category News Views 189

BioSyent Inc. to Announce Q3 Financial Results BioSyent Inc., a prominent player in the specialty pharmaceutical industry, is preparing to release its financial results for the third quarter and year-to-date period. This important announcement is scheduled for November 20, prior to the market opening. The report will cover the company's performance for the three and nine...

Continue Reading
Dr. Ryan Egeland Joins Solventum as Chief Medical Officer

Updated Category News Views 381

Solventum Welcomes Dr. Ryan Egeland as New CMO Solventum, a pioneering healthcare company, recently announced the appointment of Dr. Ryan Egeland, MD, as their Chief Medical Officer. In this significant role, Dr. Egeland will lead the Global Medical and Clinical Affairs team, amplifying clinician and patient voices within the organization. Fostering Collaboration and...

Continue Reading
MiningToken Revolutionizes Cryptocurrency With AI Power

Updated Category News Views 186

Introducing MiningToken's Innovative AI Cloud Mining Service Bitcoin and Ethereum are experiencing remarkable market dynamics as Bitcoin persists in a bullish trend and Ethereum has gained notable ground recently. As global interest in cryptocurrencies grows, effective mining strategies are crucial for profitability. Amidst rising operational costs, many individuals seek...

Continue Reading
Saluda Medical's EVA™ Sensing Technology Approved in Europe

Updated Category News Views 111

Saluda Medical Achieves Regulatory Milestone with EVA™ Technology Saluda Medical, Inc. (ASX:SLD) has made significant strides in the medical device industry by achieving CE certification for its next-generation EVA™ Sensing Technology. This advancement not only marks a major endorsement in Europe but also is recognized in Australia. Following FDA approval in December...

Continue Reading
ReadPartner Inc. Unveils Revolutionary AI Tool to Combat Misinformation

Updated Category News Views 291

ReadPartner Inc. Launches AI Feature to Tackle Misinformation ReadPartner Inc., a leader in AI-driven media intelligence solutions, is excited to announce the upcoming launch of a groundbreaking digital security feature named ProfileScreen. This innovative tool aims to address the pressing issue of misinformation that plagues social media platforms. The ProfileScreen...

Continue Reading